Cargando…

Performance of a new natural oral contrast agent (LumiVision®) in dynamic MR swallowing

OBJECTIVES: To evaluate image quality by first use of LumiVision® in dynamic MR swallowing, a contrast medium consisting of biological substances versus a gadolinium-buttermilk mixture in patients who underwent Nissen fundoplication due to gastroesophageal reflux disease (GERD). METHODS: The protoco...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulinna-Cosentini, Christiane, Arnoldner, Michael A., Schima, Wolfgang, Kristo, Ivan, Schoppmann, Sebastian F., Weber, Michael, Cosentini, Enrico P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523424/
https://www.ncbi.nlm.nih.gov/pubmed/33893856
http://dx.doi.org/10.1007/s00330-021-07927-5
_version_ 1784585297773723648
author Kulinna-Cosentini, Christiane
Arnoldner, Michael A.
Schima, Wolfgang
Kristo, Ivan
Schoppmann, Sebastian F.
Weber, Michael
Cosentini, Enrico P.
author_facet Kulinna-Cosentini, Christiane
Arnoldner, Michael A.
Schima, Wolfgang
Kristo, Ivan
Schoppmann, Sebastian F.
Weber, Michael
Cosentini, Enrico P.
author_sort Kulinna-Cosentini, Christiane
collection PubMed
description OBJECTIVES: To evaluate image quality by first use of LumiVision® in dynamic MR swallowing, a contrast medium consisting of biological substances versus a gadolinium-buttermilk mixture in patients who underwent Nissen fundoplication due to gastroesophageal reflux disease (GERD). METHODS: The protocol of this retrospective study was approved by the local Institutional Review Board. A hundred twenty-nine patients (146 examinations) underwent a dynamic MR swallowing study (at 1.5 T or 3.0 T) and received an oral contrast agent. Two readers evaluated the distention of the esophagus, contrast, and traceability of the bolus in a 3-point scale. A steady-state coherent sequence (B-FFE, TrueFISP) was used. The patients were divided into 3 different groups: 53 patients received gadolinium chelate (Dotarem®)–buttermilk mixture (GBM) in a dilution of 1:40 as an oral contrast agent; 44 patients received LumiVision® water mixture (LWM) in a dilution of 1:1 and 49 patients received LumiVision® (L) undiluted. RESULTS: GBM showed significantly better results in overall evaluation for both readers in contrast to LWM (p = .003, p = .002). L also reached significantly better results in overall evaluation than LWM in both readers (p = .004, p = .042). There was no significant difference in the overall evaluation between L and GBM (p = .914, p = .376).According to Landis and Koch, interobserver agreement was “substantial” (Cohen’s kappa = 0.738) between both readers. CONCLUSION: LumiVision® undiluted showed equal image quality compared to gadolinium-buttermilk mixture. The constellation of LumiVision® water mixture led to a clearly negative result in relation to the image quality compared to LumiVision® undiluted. Therefore, oral ingestion of LumiVision® undiluted is recommended for MR swallowing examinations. KEY POINTS: • LumiVision® undiluted shows significantly better image quality in comparison to LumiVision® diluted in oral application in swallowing MRI. • LumiVision® undiluted shows equal image quality in comparison to gadolinium-buttermilk mixture in oral application. • Oral ingestion of LumiVision® undiluted can replace gadolinium-buttermilk mixture in oral MR examinations.
format Online
Article
Text
id pubmed-8523424
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-85234242021-10-22 Performance of a new natural oral contrast agent (LumiVision®) in dynamic MR swallowing Kulinna-Cosentini, Christiane Arnoldner, Michael A. Schima, Wolfgang Kristo, Ivan Schoppmann, Sebastian F. Weber, Michael Cosentini, Enrico P. Eur Radiol Gastrointestinal OBJECTIVES: To evaluate image quality by first use of LumiVision® in dynamic MR swallowing, a contrast medium consisting of biological substances versus a gadolinium-buttermilk mixture in patients who underwent Nissen fundoplication due to gastroesophageal reflux disease (GERD). METHODS: The protocol of this retrospective study was approved by the local Institutional Review Board. A hundred twenty-nine patients (146 examinations) underwent a dynamic MR swallowing study (at 1.5 T or 3.0 T) and received an oral contrast agent. Two readers evaluated the distention of the esophagus, contrast, and traceability of the bolus in a 3-point scale. A steady-state coherent sequence (B-FFE, TrueFISP) was used. The patients were divided into 3 different groups: 53 patients received gadolinium chelate (Dotarem®)–buttermilk mixture (GBM) in a dilution of 1:40 as an oral contrast agent; 44 patients received LumiVision® water mixture (LWM) in a dilution of 1:1 and 49 patients received LumiVision® (L) undiluted. RESULTS: GBM showed significantly better results in overall evaluation for both readers in contrast to LWM (p = .003, p = .002). L also reached significantly better results in overall evaluation than LWM in both readers (p = .004, p = .042). There was no significant difference in the overall evaluation between L and GBM (p = .914, p = .376).According to Landis and Koch, interobserver agreement was “substantial” (Cohen’s kappa = 0.738) between both readers. CONCLUSION: LumiVision® undiluted showed equal image quality compared to gadolinium-buttermilk mixture. The constellation of LumiVision® water mixture led to a clearly negative result in relation to the image quality compared to LumiVision® undiluted. Therefore, oral ingestion of LumiVision® undiluted is recommended for MR swallowing examinations. KEY POINTS: • LumiVision® undiluted shows significantly better image quality in comparison to LumiVision® diluted in oral application in swallowing MRI. • LumiVision® undiluted shows equal image quality in comparison to gadolinium-buttermilk mixture in oral application. • Oral ingestion of LumiVision® undiluted can replace gadolinium-buttermilk mixture in oral MR examinations. Springer Berlin Heidelberg 2021-04-24 2021 /pmc/articles/PMC8523424/ /pubmed/33893856 http://dx.doi.org/10.1007/s00330-021-07927-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Gastrointestinal
Kulinna-Cosentini, Christiane
Arnoldner, Michael A.
Schima, Wolfgang
Kristo, Ivan
Schoppmann, Sebastian F.
Weber, Michael
Cosentini, Enrico P.
Performance of a new natural oral contrast agent (LumiVision®) in dynamic MR swallowing
title Performance of a new natural oral contrast agent (LumiVision®) in dynamic MR swallowing
title_full Performance of a new natural oral contrast agent (LumiVision®) in dynamic MR swallowing
title_fullStr Performance of a new natural oral contrast agent (LumiVision®) in dynamic MR swallowing
title_full_unstemmed Performance of a new natural oral contrast agent (LumiVision®) in dynamic MR swallowing
title_short Performance of a new natural oral contrast agent (LumiVision®) in dynamic MR swallowing
title_sort performance of a new natural oral contrast agent (lumivision®) in dynamic mr swallowing
topic Gastrointestinal
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523424/
https://www.ncbi.nlm.nih.gov/pubmed/33893856
http://dx.doi.org/10.1007/s00330-021-07927-5
work_keys_str_mv AT kulinnacosentinichristiane performanceofanewnaturaloralcontrastagentlumivisionindynamicmrswallowing
AT arnoldnermichaela performanceofanewnaturaloralcontrastagentlumivisionindynamicmrswallowing
AT schimawolfgang performanceofanewnaturaloralcontrastagentlumivisionindynamicmrswallowing
AT kristoivan performanceofanewnaturaloralcontrastagentlumivisionindynamicmrswallowing
AT schoppmannsebastianf performanceofanewnaturaloralcontrastagentlumivisionindynamicmrswallowing
AT webermichael performanceofanewnaturaloralcontrastagentlumivisionindynamicmrswallowing
AT cosentinienricop performanceofanewnaturaloralcontrastagentlumivisionindynamicmrswallowing